Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

Merck discontinues MK-1903 niacin receptor agonist development program with Arena Pharmaceuticals

Arena Pharmaceuticals, Inc. announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed Arena that the company will not continue the collaboration.

24 Dec 2009

Arizona State University and Mayo Clinic team up to explore metabolic syndrome

Arizona State University and Mayo Clinic in Arizona are joining forces in a partnership to investigate metabolic syndrome - a cluster of high-risk medical factors that include increased blood pressure, elevated insulin levels, excess body fat and abnormal cholesterol levels, which can lead to heart disease, stroke and diabetes.

16 Dec 2009

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR®

16 Dec 2009

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

AstraZeneca and the University of Virginia (UVa) in Charlottesville, today announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

15 Dec 2009

Abbott submits SIMCOR sNDA for two new dosage strengths

Abbott has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new dosage strengths of SIMCOR®, a cholesterol medication. SIMCOR is a fixed-dose combination of niacin extended-release and simvastatin.

10 Dec 2009

Merck to commence MK-6913 phase IIa efficacy trial for treatment of hot flashes/hot flushes

The Swedish biotech company Karo Bio today announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.

26 Nov 2009

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.

16 Nov 2009

Phase I clinical study for ETC-1002 commenced

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

16 Nov 2009

Report on the epidemiology of PAD, TAO and CLI in India

A new analysis published by THE SAGE GROUP concludes that atherosclerotic peripheral arterial disease (PAD) afflicts over 20 million in India. Both PAD and CLI represent major and significantly underestimated problems for the Indian economy and healthcare system.

13 Nov 2009

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.

29 Oct 2009

New CCS guidelines and position papers for physicians and nurse practitioners

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

28 Oct 2009

PPD plans to separate compound partnering business from CRO business; spin-off to result in independent public companies

PPD, Inc. today announced its board of directors has authorized management to proceed with preparations to spin off its compound partnering business from its core contract research organization, or CRO, business.

28 Oct 2009

LIVALO statin effective than simvastatin in reducing lipid levels

New Phase III data published today in "Current Medical Research and Opinion" highlight that the recommended starting dose of 2 mg of LIVALO (pitavastatin), a novel synthetic statin, was statistically superior to simvastatin at a dose of 20 mg over 12 weeks in reducing low-density lipoprotein cholesterol

22 Oct 2009

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation.

20 Oct 2009

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace’), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.

19 Oct 2009

Amarin raises $70 million through private placement

Amarin Corporation plc today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Cowen and Company, LLC acted as the exclusive placement agent for the transaction.

19 Oct 2009

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

AstraZeneca today announced the U.S. Food and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease.

19 Oct 2009

Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from two multiple ascending dose Phase 1 clinical trials of MBX-2982.

14 Oct 2009

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it will present new genetic findings in the fields of obesity and osteoporosis at medical meetings later this month.

13 Oct 2009

Dyslipidemia News and Research

Merck discontinues MK-1903 niacin receptor agonist development program with Arena Pharmaceuticals

Arizona State University and Mayo Clinic team up to explore metabolic syndrome

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

Abbott submits SIMCOR sNDA for two new dosage strengths

Merck to commence MK-6913 phase IIa efficacy trial for treatment of hot flashes/hot flushes

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Phase I clinical study for ETC-1002 commenced

Report on the epidemiology of PAD, TAO and CLI in India

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

New CCS guidelines and position papers for physicians and nurse practitioners

PPD plans to separate compound partnering business from CRO business; spin-off to result in independent public companies

LIVALO statin effective than simvastatin in reducing lipid levels

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

Amarin raises $70 million through private placement

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News